Maven Securities LTD Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Maven Securities LTD bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 150,000 shares of the biotechnology company's stock, valued at approximately $2,070,000. Maven Securities LTD owned approximately 0.33% of Capricor Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after buying an additional 37,868 shares during the last quarter. Magnus Financial Group LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $276,000. Swiss National Bank purchased a new position in Capricor Therapeutics in the fourth quarter valued at approximately $930,000. JPMorgan Chase & Co. raised its holdings in Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after purchasing an additional 45,381 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $183,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Trading Up 12.1%

Shares of CAPR stock opened at $7.11 on Tuesday. The company has a market capitalization of $324.76 million, a P/E ratio of -6.71 and a beta of 0.85. The business's 50 day moving average is $11.05 and its two-hundred day moving average is $14.03. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. As a group, equities analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CAPR. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.